Biotech funding bill hits Senate

A biotech funding bill that extends SBIR and STTR past an impending sunset has reached the floor of the senate after clearing the House of Representatives in April.

The bill in its current form will add 14 years to the lifespans of both the SBIR and STTR programs and increase the funding available in phase I and phase II awards, and it will broaden eligibility for participants in some key areas. 

See The Scientist.com article for more detail.